About Kymeratx
Kymeratx is a company based in Cambridge (United States) founded in 2016 by Nello Mainolfi and Steven Robinette. Kymeratx has raised $197 million across 4 funding rounds from investors including Bessemer Venture Partners, BlackRock and Atlas Venture. The company has 188 employees as of December 31, 2024. Kymeratx offers products and services including KT-621 and Pipeline Therapeutics. Kymeratx operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Revolution Medicines, Blueprint Medicines and Syndax, among others.
- Headquarter Cambridge, United States
- Employees 188 as on 31 Dec, 2024
- Founders Nello Mainolfi, Steven Robinette
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kymera Therapeutics, Inc.
-
Annual Revenue
$47.07 M (USD)-40.11as on Dec 31, 2024
-
Net Profit
-$223.86 M (USD)-52.32as on Dec 31, 2024
-
EBITDA
-$249.34 M (USD)-53.94as on Dec 31, 2024
-
Total Equity Funding
$197 M (USD)
in 4 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Aug 19, 2022
-
Investors
Bessemer Venture Partners
& 19 more
-
Employee Count
188
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kymeratx
Kymeratx is a publicly listed company on the NASDAQ with ticker symbol KYMR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Kymeratx
Kymeratx offers a comprehensive portfolio of products and services, including KT-621 and Pipeline Therapeutics.
Oral degrader for treating Atopic Dermatitis and related conditions.
First-in-class medicines targeting disease drivers.
People of Kymeratx
Unlock access to complete
Unlock access to complete
Leadership Team
66 people
Product Management Team
10 people
Software Development Team
9 people
Senior Team
9 people
Principal Team
7 people
Scientific Team
7 people
Operations Team
7 people
Human Resources and Administration
6 people
Unlock access to complete
Funding Insights of Kymeratx
Kymeratx has successfully raised a total of $197M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kymeratx
Kymeratx has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Bessemer Venture Partners, BlackRock and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Kymeratx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kymeratx
Investment portfolio details for Kymeratx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kymeratx
Detailed financials for Kymeratx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kymeratx Comparisons
Peer comparison for Kymeratx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kymeratx
Kymeratx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Revolution Medicines, Blueprint Medicines and Syndax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
Detailed competitors of Kymeratx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kymeratx
Complete news archive for Kymeratx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kymeratx
Kymeratx was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Kymeratx is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Nello Mainolfi is the current CEO of Kymeratx. They have also founded this company.
Kymeratx is a funded company, having raised a total of $197M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Kymeratx is 188.
Annual revenue of Kymeratx is $47.07M as on Dec 31, 2024.
Kymeratx was founded in 2016 in Cambridge, United States, within the biotechnology sector. Small molecule protein degraders are developed to target IRAK4, IRAKIMiD, and STAT3, addressing immune-inflammatory diseases, hematologic malignancies, and solid tumors. Targeted protein degradation platforms are provided, based on the ubiquitin-proteasome systems role in cellular regulation. Operations focus on therapeutic applications for these conditions.
Kymeratx's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
Kymeratx offers KT-621 and Pipeline Therapeutics.
Yes, Kymeratx is publicly traded on NASDAQ under the ticker symbol KYMR.
Kymeratx has 20 investors. Key investors include Bessemer Venture Partners, BlackRock, Atlas Venture, Aju IB Investment, and Redmile Group.
The ticker symbol of Kymeratx is KYMR on NASDAQ.